Copyright
©The Author(s) 2024.
World J Methodol. Sep 20, 2024; 14(3): 91832
Published online Sep 20, 2024. doi: 10.5662/wjm.v14.i3.91832
Published online Sep 20, 2024. doi: 10.5662/wjm.v14.i3.91832
Table 3 Patients’ glycated hemoglobin before and after treatment with semaglutide
| Attributes | Male | Female | All | Reference value (if applicable) | |||
| Mean | (SD) | Mean | (SD) | Mean | (SD) | ||
| Patient baseline HbA1c (mmol/mol) | 84.18 | (22.20) | 79.46 | (19.40) | 81.96 | (20.96) | 20-41 mmol/mol |
| HbA1c after 6 months (mmol/mol) | 68.52 | (21.06) | 67.02 | (15.66) | 67.79 | (18.53) | 20-41 mmol/mol |
| HbA1c after 1 yr (mmol/mol) | 71.42 | (21.94) | 63.27 | (17.48) | 66.91 | (19.88) | 20-41 mmol/mol |
| Latest HbA1c (mmol/mol) | 72.98 | (25.60) | 68.2 | (19.80) | 70.73 | (23.04) | 20-41 mmol/mol |
- Citation: Alkhalifah M, Afsar H, Shams A, Blaibel D, Chandrabalan V, Pappachan JM. Semaglutide for the management of diabesity: The real-world experience. World J Methodol 2024; 14(3): 91832
- URL: https://www.wjgnet.com/2222-0682/full/v14/i3/91832.htm
- DOI: https://dx.doi.org/10.5662/wjm.v14.i3.91832